EGFRIndb: Epidermal Growth Factor Receptor Inhibitor database
|
|
- Anis Casey
- 6 years ago
- Views:
Transcription
1 EGFRIndb: Epidermal Growth Factor Receptor Inhibitor database Inderjit S Yadav 1,3, Harinder Singh 2, Mohd. Imran Khan 1, Ashok Chaudhury 3, G.P.S. Raghava 2 and Subhash M. Agarwal 1 * 1 Bioinformatics Division, Institute of Cytology and Preventive Oncology, Noida , India 2 Bioinformatics Centre, Institute of Microbial Technology, Sector 39A, Chandigarh, India 3 Department of Bio & Nano Technology, Guru Jambhehswar University Science & Technology, Hisar, India * Corresponding author Dr. Subhash Mohan Agarwal Bioinformatics Division Institute of Cytology and Preventive Oncology I-7, Sector-39, Noida India address: smagarwal@yahoo.com
2 Background Aberrant activity of epidermal growth factor receptor (EGFR) family proteins has been found to be associated with a number of human cancers including lung and breast. Consequently, the search for EGFR family inhibitors, a well established target of pharmacological and therapeutic value has been ongoing. Therefore, over the years several small molecules, which compete for ATP in the kinase domain had been synthesised and some of them have proved to be effective in attenuating EGFR mediated proliferation. Thus, there exists in literature a vast amount of experimental data on EGFR tyrosine kinase inhibitors. In this paper, we describe a comprehensive database EGFRIndb that contains details of the small molecular inhibitors of EGFR family. Description EGFRIndb is a literature curated database of small synthetic molecular inhibitors of EGFR. It consists of 4581 compounds showing in vitro inhibitory activities (IC 50, IC 80, GI 50, GI 90, EC 50, K i, K d and percentage inhibition) either against EGFR or its different isoforms i.e. Erbb2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2) and Erbb4 (v-erbb2 avian erythroblastic leukemia viral oncogene homolog 4) or various mutants. For each compound, database provides information on structure, experimentally determined inhibitory activity of compound against kinase as well as various cell lines, properties (physical, elemental and topological) and drug likeness. Additionally, it provides information on irreversible as well as dual inhibitors that have gained importance in recent years due to the emergence of clinical resistance to known drugs. As compound activity against similar kinases is a measure of its selectivity and specificity, the database also provides this information. It also provides simple search, advanced search, browse facility as well as a tool for structure based searching. Conclusion EGFRIndb gathers biological and chemical information on EGFR inhibitors from the literature. It is hoped that it will serve as a useful resource in drug discovery and provide data for docking, virtual screening and Quantitative structure activity relationship (QSAR) model development to the cancer researchers. Keywords Database; Epidermal growth factor receptor; Cancer; Tyrosine kinase inhibitors; Dual inhibitors; Irreversible Inhibitors
3 1. Introduction The epidermal growth factor receptor (EGFR) is a member of receptor tyrosine kinase family. It is a trans-membrane protein consisting of four closely related isoforms: EGFR/ErbB1/Her1, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. All the members share the common architecture consisting of three main domains: extracellular ligand binding domain, a trans-membrane domain and an intracellular kinase domain [1]. Each member of the EGFR family is a potent mediator of normal cell growth and development [2, 3]. The three isoforms-egfr, ERbB2 and ERbB3 are all implicated in the development and progression of various cancers while the fourth-erbb4 is suggested to be involved in inhibition of cell growth rather than proliferation [3]. The association between EGFR and various cancers including non small cell lung cancer has been well established in the past two decades [4, 5]. Similarly, overexpression/amplification of ErbB2 has been reported in a number of human tumors including 25% to 30% of breast cancer cases [6], ovarian and gastric cancer [3]. Thus, both EGFR and ErbB2 receptors among the EGFR family members have been well-characterised and got established as a pharmacologically validated target for cancer therapy [7]. As a result, in the past several years a number of small molecule tyrosine kinase inhibitors (TKIs) were developed and are currently available as therapeutics including first clinically used gefitinib (Irressa) [8] and erlotinib (Tarceva) [9], afatinib (Tomtovok) [10] and dual inhibitor of EGFR and ErbB2 like lapatinib (Tykerb) [11]. The treatment of patients with EGFR or ErbB2 based inhibitors as targeted therapy thus has shown a significant reduction in the cancer progression [12]. Clinically it is well established that protein kinase inhibitors play a significant role in the treatment of cancer. According to a recent paper, out of 24 small-molecule kinase inhibitors approved for use as therapeutic agents 17 are for cancer [13]. It is also established that a significant proportion of activity in oncology industry is directed on only eight common kinase targets which includes EGFR and HER2 [13]. Over the period, biological activity of a large number of molecules has been published, which if pooled would be useful for analysis and decision making in drug discovery. In recent years, a number of literaturecurated databases related to genetic or mechanistic aspect of cancer have been developed [14-16]. Also, a specialised database of somatic mutations of the tyrosine kinase domain of EGFR (SM-EGFR-DB) that catalogues EGFR somatic mutations identified in human cancers from literature has been established [17]. Similarly, a number of excellent small compound repository like Pubchem ( a database consisting of structures and biological activities of small organic molecules, Chemical Entities of Biological Interest (ChEBI) which provides the oncological classification of compounds along with the structural information [18] and DrugBank which is a resource for known drugs and their targets has been developed [19]. As a result of emergence of EGFR family as a pharmacological target and success of protein kinase inhibitors as treatment agent of cancer, a number of researchers have continuously synthesised small molecules and investigated them for anti-egfr activity using a variety of in vitro cellular and enzymatic assay systems. This resulted in identification of a variety of bioactive compounds making a large amount of biological and structural information available in the public domain. In spite of such a huge amount of data available in biomedical literature on EGFR inhibitors, to our knowledge there is no dedicated resource
4 available that collectively provides information on these molecules under one platform. Keeping the importance of EGFR kinase inhibitor in anticancer therapeutics and to complement other databases we have developed EGFRIndb database ( EGFRIndb is a database of 4581 small molecules that have shown activity against either of EGFR isoforms (EGFR, ErbB2, ErbB4) or mutants of EGFR-TK domain. It is expected that availability of EGFRIndb would facilitate better understanding of the molecular space and its associated complexity with reference to EGFR family inhibitors.
5 2. Construction and content 2.1 Data source, compilation and structure For collection of compounds which have shown inhibition against different EGFR isoforms or its mutants, we have extensively searched literature using PubMed and other resources like google scholar with different keywords or their combination to find the research articles. Some of the keywords that were used for systematic searching from PubMed are EGFR inhibitors, Erbb2 inhibitors, EGFR dual inhibitors, EGFR irreversible inhibitors, EGFR covalent inhibitors, EGFR mutant inhibitors. The main criterion for inclusion of the compounds in the database was it must have activity against EGFR or its isoforms Erbb2 and Erbb4 or its mutants. Once collected, we read through these articles for obtaining the different standard inhibition values like IC 50 (concentration required for 50% inhibition), IC 80 (concentration required for 80% inhibition), GI 50 (concentrations required to inhibit the growth by 50%), GI 90 (concentrations required to inhibit the growth by 90%), EC 50 (half maximal effective concentration), ED 50 (effective dose required to produce a therapeutic response in 50% of the population), K i (inhibition constant), K d (dissociation constant) and percentage inhibition. We also gathered information whether the inhibition constants have been investigated either using enzymatic assay or against the cell line under in vitro conditions. Finally, we noted the cell line, corresponding inhibition values along with the literature id (PMID). As in recent years, a number of activating or resistant mutations have been documented in literature, the information of the compounds inhibiting these mutant isoforms like L858R, T790M and double mutant L858R/T790M was also extracted. Further, to understand the inhibition mechanism of these compounds, they were classified into reversible and irreversible inhibitors. The 2D and 3D structures of the collected molecules were drawn using Marvinsketch 5.4.1, a chemical drawing tool, which is a part of Chemaxon package ( A majority of research articles describe the structures as a common scaffold with different functional groups as variants, therefore utmost care has been taken while drawing the structures. Different structural and topological molecular descriptors were calculated for each molecule using the Marvinsketch5.4.1, which includes mass, IUPAC name, composition, InChI (IUPAC International Chemical Identifier), InChiKey, SMILES, SMART, pi, logp, vander waals volume, polar surface area (PSA), h-bond donor and acceptors counts, no. of chiral centers and double bond etc. InChI is an identifier for chemical substances which is used in printed and electronic data to enable easier linking of diverse data compilations ( InChIKey is a 27-character compacted (hashed) version of InChI that is designed for internet and database searching/indexing [20]. Simplified Molecular-Input Line-Entry System (SMILES) is a specification in the form of a line notation for describing the structure of chemical molecules using short ASCII strings [21] while SMiles ARbitrary Target Specification (SMARTS) is a language for specifying substructural patterns in molecules ( Once all the information was gathered, the data was fed into different tables. Overall, EGFRIndb is divided into seven tables (i) general molecule description table which contains the basic information about the
6 molecule like compound Id (unique), PubChem ID, InChi, InChi key, SMART, SMILES and so forth (ii) enzyme activity table which harbours the information of inhibition activity of compound against different EGFR isoforms (EGFR/ErbB2/ErbB4) or its mutants (iii) cellular activity table which details the inhibition values of compound against different cell lines (iv) target table includes information of other protein targets inhibited by the compound along with its inhibitory value (v) property table containing elemental information of compound (vi) topology information table and (vii) filter table containing information about computed filters (Lipinski s rule of five, ghose filter, veber filter, mugge s filter and bioavailability) (Figure 1). The server is launched from a Red Hat based xeon server using Apache and the frontend has been developed using PHP programming language with MySQL ( an open source relational database management system at the backend.
TTI-2341: A Novel Brain-Penetrant, Orally Available, Covalent EGFR Inhibitor for the Treatment of Brain Cancers
TTI-2341: A Novel Brain-Penetrant, Orally Available, Covalent EGFR Inhibitor for the Treatment of Brain Cancers November 2017 2 EGFR is a Drug Target in Brain Cancer Epidermal growth factor receptor (EGFR)
More informationEts-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs
Ets-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs Indian Patent Application No. 1623/DEL/2014 Inventors: Prof. Kulbhushan Tikoo and Jasmine Kaur Department of Pharmacology
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationIs there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma?
Is there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma? Juan M Sepúlveda Sánchez Neurooncology Unit Hospital Universitario 12 de Octubre. Madrid Topics 1.-EGFR pathway as a potential
More informationAllosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor!
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor Allosteric pocket SHP2 Phosphatase ovel allosteric Phosphatase inhibitor Evan Carder Wipf
More informationThe PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction
The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationEGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling
EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationMolecular targeted therapeutics for the treatment of cancer patients. August 1, 2016
Molecular targeted therapeutics for the treatment of cancer patients August 1, 2016 Company overview Experienced team with value creating track record in the field of targeted oncology Validated targets
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationTime Minimizing in anticancer drug discovery. Farida Suhud University of Surabaya, Raya Kalirungkut, Surabaya, Indonesia
Time Minimizing in anticancer drug discovery Farida Suhud University of Surabaya, Raya Kalirungkut, Surabaya, Indonesia Abstract Farida Suhud University of Surabaya, Raya Kalirungkut, Surabaya, Indonesia
More informationMeasuring interaction complexity and time to equilibrium for biotherapeutics in whole cell assays. Karl Andersson Uppsala University Sweden
Measuring interaction complexity and time to equilibrium for biotherapeutics in whole cell assays Karl Andersson Uppsala University Sweden Who am I? Affiliated with Uppsala University and Ridgeview Instruments
More informationTargeting the ERBB family in cancer: couples therapy
OPINION Targeting the ERBB family in cancer: couples therapy Niall Tebbutt, Mikkel W. Pedersen and Terrance G. Johns Abstract The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis
More informationJournal of Chemical and Pharmaceutical Research, 2016, 8(9): Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(9):73-80 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 QSAR and Docking Studies of Pubchem Derivatives as
More informationIntroduction to Targeted Therapy
Introduction to Targeted Therapy Cancer remains the second leading cause of death in the United States, despite the significant advances in cancer therapy made over the past several decades. Many factors
More informationOsimertinib (AZD9291) a science-driven, collaborative approach
Annals of Oncology Advance Access published March 8, 2016 1 Osimertinib (AZD9291) a science-driven, collaborative approach to rapid drug design and development A. Yver Global Medicines Development, AstraZeneca,
More informationOncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies
OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies 2017 Contents Datasets... 2 Protein-protein interaction dataset... 2 Set of known PPIs... 3 Domain-domain interactions...
More informationComputer Aided Docking Studies on Anticancer Drugs for Breast Cancer
International Journal of Information & Computation Technology. ISSN 0974-2239 Volume 2, Number 1 (2012), pp. 49-55 International Research Publications House http://www. ripublication.com Computer Aided
More informationMolecular Oncology, oncology parameters see each test
Molecular Oncology, oncology parameters see each test DPD deficiency Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is an autosomal recessive metabolic disorder in which there is absent or
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tagrisso) Reference Number: CP.PHAR.294 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationAsian Journal of Biomedical and Pharmaceutical Sciences 1 (6) 2012, 01-05
Asian Journal of Biomedical and Pharmaceutical Sciences 1 (6) 2012, 01-05 RESEARCH ARTICLE ISSN 2249-622X Virtual Screening of Xanthones in Combating Malaria Targeting Plasmodium Falciparum Erythrocyte
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationIn vitro and in vivo evaluation of two enantiomers of Nanocyclix EGFR targeted PET radiotracer
In vitro and in vivo evaluation of two enantiomers of Nanocyclix targeted PET radiotracer Authors Petra Blom 1,2, livier Raguin 1,2, Celine Mothes 2,3, Peggy Provent 1,2, Guillaume Serin 1, Xavier Tizon
More informationAn Updated Comparison of Selected Public and Commercial Bioactive Chemistry Databases
An Updated Comparison of Selected Public and Commercial Bioactive Chemistry Databases Christopher Southan The International Conference for Science & Business Information Sitges, Spain, October 2009 http://www.cdsouthan.info/consult/cds_cons.htm
More informationTargeted Therapeutics for the Treatment of Cancer
Targeted Therapeutics for the Treatment of Cancer Company overview Three promising targeted anti-cancer programs Irreversible pan-erbb inhibitor EGFR/HER2/HER4 inhibitor PARP inhibitor Strategy Focus on
More informationAn Update on EGFR Inhibitors. Disclosure. Objectives 4/1/2011. Leigh M. Boehmer, Pharm.D., has no real or apparent conflicts of interest to report
An Update on EGFR Inhibitors Leigh M. Boehmer, Pharm.D., BCOP Clinical Pharmacist, Medical Oncology Barnes Jewish Hospital Saint Louis, Missouri Disclosure Leigh M. Boehmer, Pharm.D., has no real or apparent
More informationTranslational Bioinformatics: Connecting Genes with Drugs
Translational Bioinformatics: Connecting Genes with Drugs Aik Choon Tan, Ph.D. Associate Professor of Bioinformatics Division of Medical Oncology Department of Medicine aikchoon.tan@ucdenver.edu 11/14/2017
More informationHomo sapiens ERBB2 erb-b2 receptor tyrosine kinase 2
International Research Journal of Biological Sciences ISSN 2278-3202 Comparative analysis of Homo sapiens ERBB2 erb-b2 receptor tyrosine kinase 2 Abstract Shahid Raza 1, Muhammad Waseem Shoaib 2 and Hira
More informationIn silico approach of compounds in Cissus quadrangularis targeting multiproteins as anticancer agents
Research Article In silico approach of compounds in Cissus quadrangularis targeting multiproteins as anticancer agents C. N. Hemalatha 1, Elancheziyan K 1, D. Pavithra 2, M. Vijey Aanandhi 3 * ABSTRACT
More informationMolecular Docking Studies on Pyrazolopyrimidine and their Derivatives as Human Phosphoinositide 3-Kinase Inhibitors
Cloud Publications International Journal of Advanced Bioinformatics and Computational Biology 2012, Volume 1, Issue 1, pp. 1-11, Article ID Med-30 Research Article Open Access Molecular Docking Studies
More informationStructure-based analysis of curcumin and conventional drugs targeting tumor-inducing protein PHF20
www.bioinformation.net Volume 14(9) Hypothesis Structure-based analysis of curcumin and conventional drugs targeting tumor-inducing protein PHF20 Vibha Agrawal 1, Aradhya Mishra 1, Shivani Tiwari 1, Akhileshwar
More informationLIGAND BASED PHARMACOPHORE DEVELOPMENT FOR COLORECTAL CANCER DRUGS
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-2566 LIGAND BASED PHARMACOPHORE DEVELOPMENT FOR COLORECTAL CANCER DRUGS 1. PhD Scholar (Bioinformatics) M.A.J.U. Islamabad. 2. Postgraduate
More informationLife History of A Drug
DRUG ACTION & PHARMACODYNAMIC M. Imad Damaj, Ph.D. Associate Professor Pharmacology and Toxicology Smith 652B, 828-1676, mdamaj@hsc.vcu.edu Life History of A Drug Non-Specific Mechanims Drug-Receptor Interaction
More informationTyrosine kinases. Cell surface receptors ligand binding. Producer cell RNA. Target cell
Tyrosine kinases http://msbl.helsinki.fi/tkseminar roducer cell Signaling molecules Receptor binding Signal transduction Target cell Activation of Gene expression RNA Biological responses proliferation,
More informationAvailable Online through
ISS: 0975-766X CDE: IJPTFI Available nline through Research Article www.ijptonline.com RELATISHIP BETWEE SCRIG FUCTI AD THE IC 50 IHIBITRY F PI3K IHIBITRS Awantika Shrivastava*, Dr.K.Durga Prasad 1, Dr.
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationINSILICO DOCKING AND INTERACTION ANALYSIS OF ELLAGIC ACID AND CURCUMIN DERIVATIVES AGAINST HUMAN CANCER
ISSN: 0976-2876 (Print) ISSN: 2250-0138(Online) INSILICO DOCKING AND INTERACTION ANALYSIS OF ELLAGIC ACID AND CURCUMIN DERIVATIVES AGAINST HUMAN CANCER NAYANA MOHAN a AND M.S. LATHA b1 ab Department of
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationVirtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors
www.bioinformation.net Hypothesis Volume 9(11) Virtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors Monika 1 *, Janmeet Kour 1 & Kulwinder Singh 2 1Department of Biotechnology,
More informationCell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger
Cell, Volume 141 Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Figure S1. RTK Mutations in Diseases Locations of gain-of-function (green arrows)
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): The authors have presented data demonstrating activation of AKT as a common resistance mechanism in EGFR mutation positive, EGFR TKI resistant
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationSALSA MLPA probemix P315-B1 EGFR
SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional
More informationDr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
More informationThe absence of the ERBB4 hotspot mutations in melanomas in patients from southern China
Brief Report The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China Qi-Ming Zhou 1,2,5*, Wei Li 6*, Yuan-Xiang Guan 1,3, Xing Zhang 1,2, Xin-Chun Chen 6, Ya Ding 1,2, Xi-Zhi
More informationRociletinib (CO-1686) April, 2015
Rociletinib (CO-1686) April, 2015 Lung adenocarcinoma is increasingly treated according to driver mutation Lung cancer incidence Worldwide: 1.2M cases per year UK: 43K cases per year Activating mutations
More informationTumor mutational burden and its transition towards the clinic
Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:
Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationMolecular Docking Studies of Flavonoids of Noni Fruit (Morinda citrifolia L.) to Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ)
3rd International Conference on Computation for Science and Technology (ICCST-3) Molecular Docking Studies of Flavonoids of Noni Fruit (Morinda citrifolia L.) to Peroxisome Proliferator-Activated Receptor-Gamma
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1104-7 Program Prior Authorization/Notification Medication Tarceva (erlotinib) P&T Approval Date 8/2008, 6/2009, 6/2010, 9/2010,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationDeveloping Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014
Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic Kevin G. McLure, PhD EpiCongress July 2014 Zenith Epigenetics Overview Formed from Resverlogix as an independent
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationMulti-Center Phase III Clinical Trials and NCI Cooperative Groups. Dr. John E. Niederhuber Director, National Cancer Institute July 1, 2008
Multi-Center Phase III Clinical Trials and NCI Cooperative Groups Dr. John E. Niederhuber Director, National Cancer Institute July 1, 2008 Phase II Trial of Paclitaxel by 96-Hour Continuous Infusion Plus
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
BioDrugs (2015) 29:167 183 DOI 10.1007/s40259-015-0130-9 REVIEW ARTICLE Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Vera Hirsh 1 Published online: 30 June 2015 The
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationCOMPARATIVE VEGF RECEPTOR TYROSINE KINASE MODELING FOR THE DEVELOPMENT OF HIGHLY SPECIFIC INHIBITORS OF TUMOR ANGIOGENESIS
243 COMPARATIVE VEGF RECEPTOR TYROSINE KINASE MODELING FOR THE DEVELOPMENT OF HIGHLY SPECIFIC INHIBITORS OF TUMOR ANGIOGENESIS ULRIKE SCHMIDT 1 JESSICA AHMED 1 ulrike.schmidt@charite.de jessica.ahmed@charite.de
More informationNext Generation EGFR Inhibitors
Next Generation EGFR Inhibitors Tony Mok MD Li Shu Fan Medical Foundation Professor of Clinical Oncology Dept. of Clinical Oncology The Chinese University of Hong Kong EGFR TKIs First Generation -Gefitinib
More informationIn-Silico Analysis of Andrographolide against Cancer
Available online at www.ijpsdr.com International Journal of Pharmaceutical Sciences and Drug Research 2013; 5(2): 56-61 Research Article ISSN 0975-248X In-Silico Analysis of Andrographolide against Cancer
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationRAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.
۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationNeratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial
Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial Anishka D Souza 1, Lynda D. Roman 1, Cristina Saura 2, Irene Braña 2, Geoffrey I. Shapiro
More informationIdentification of BRAF mutations in melanoma lesions with the Roche z480 instrument
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial
More informationSignaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research
Signaling Dr. Sujata Persad 3-020 Katz Group Centre for Pharmacy & Health research E-mail:sujata.persad@ualberta.ca 1 Growth Factor Receptors and Other Signaling Pathways What we will cover today: How
More informationFundamentals of Pharmacology
Fundamentals of Pharmacology Topic Page Receptors 2 Ion channels / GABA 4 GPCR s 6 TK receptors 8 Basics of PK 11 ADR s / Clinical study design 13 Introduction to the ANS 16 Cholinergic Pharmacology 20
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationOsimertinib (lung cancer)
IQWiG Reports Commission No. A16-14 Osimertinib (lung cancer) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Osimertinib
More informationAKT apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) TNF superfamily. apoptosis TRAIL 2 apoptosis
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) TNF superfamily apoptosis TRAIL 2 apoptosis TRAIL (epidermal growth factor receptor, EGFR) EGFR EGFR EGFR-TKI) EGFR-TKI EGFR TNFIL-8IL-1IL-1
More informationDeveloping Better Medicine
SURF 2013 Marietta L. Harrison, PhD Director, Oncological Sciences Center in Discovery Park Professor, Medicinal Chemistry and Molecular Pharmacology How we do it today One size fits all Medicines aren
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationComparative Docking Studies on Neurological and Psychological disorders Genes (BDNF and CLCN2) using Cheminformatics Protocols.
Available online at www.ijntps.org ISSN: 2277 2782 INTERNATIONAL JOURNAL OF NOVEL TRENDS IN PHARMACEUTICAL SCIENCES RESEARCH ARTICLE Comparative Docking Studies on Neurological and Psychological disorders
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationSelection of Luteolin as a potential antagonist from molecular docking analysis of EGFR mutant
www.bioinformation.net Volume 14(5) Hypothesis Selection of Luteolin as a potential antagonist from molecular docking analysis of EGFR mutant George Oche Ambrose 1,6, Olanrewaju John Afees 2, Nwufoh Chika
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationTargeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationKEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationREVIEWS. Epidermal growth factor receptor mutations in lung cancer
Epidermal growth factor receptor mutations in lung cancer Sreenath V. Sharma*, Daphne W. Bell*, Jeffrey Settleman* and Daniel A. Haber* Abstract The development and clinical application of inhibitors that
More informationMolecular modelling and insilico drug docking studies on breast cancer target protein (TNRC9) using cheminformatics software and tools
Available online at www.ijntps.org ISSN: 2277 2782 INTERNATIONAL JOURNAL OF NOVEL TRENDS IN PHARMACEUTICAL SCIENCES Molecular modelling and insilico drug docking studies on breast cancer target protein
More informationPHAR3316 Pharmacy biochemistry Exam #2 Fall 2010 KEY
1. How many protons is(are) lost when the amino acid Asparagine is titrated from its fully protonated state to a fully deprotonated state? A. 0 B. 1 * C. 2 D. 3 E. none Correct Answer: C (this question
More informationa) The statement is true for X = 400, but false for X = 300; b) The statement is true for X = 300, but false for X = 200;
1. Consider the following statement. To produce one molecule of each possible kind of polypeptide chain, X amino acids in length, would require more atoms than exist in the universe. Given the size of
More informationModule 3: Pathway and Drug Development
Module 3: Pathway and Drug Development Table of Contents 1.1 Getting Started... 6 1.2 Identifying a Dasatinib sensitive cancer signature... 7 1.2.1 Identifying and validating a Dasatinib Signature... 7
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationProtein tyrosine kinase signaling
rotein tyrosine kinase signaling Serge ROCHE CRBM CNRS/Montpellier University serge.roche@crbm.cnrs.fr rotein phosphorylation on Tyr A central mechanism to control cell communication in a multicellular
More information